MX384745B - Proceso para la preparación de compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidina-2,7-diona 3-sustituidos. - Google Patents

Proceso para la preparación de compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidina-2,7-diona 3-sustituidos.

Info

Publication number
MX384745B
MX384745B MX2019008116A MX2019008116A MX384745B MX 384745 B MX384745 B MX 384745B MX 2019008116 A MX2019008116 A MX 2019008116A MX 2019008116 A MX2019008116 A MX 2019008116A MX 384745 B MX384745 B MX 384745B
Authority
MX
Mexico
Prior art keywords
thiazolo
pyrimidine
amino
substituted
sup
Prior art date
Application number
MX2019008116A
Other languages
English (en)
Other versions
MX2019008116A (es
Inventor
Jianhua Yu
Jing Xiong
Junli Chen
Manuel Konrath
Roland Meier
Xuemei Wang
Yan Ren
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2019008116A publication Critical patent/MX2019008116A/es
Publication of MX384745B publication Critical patent/MX384745B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención se refiere a un proceso para sintetizar un compuesto de fórmula (I), (I),(ver formula) R1 es H o alquilo C1-6; R2 es H o hidroxi; o una sal o diastereómero farmacéuticamente aceptable, que es útil para la profilaxis y el tratamiento de una enfermedad viral en un paciente relacionada con infección por hepatitis B o una enfermedad causada por infección por hepatitis B.
MX2019008116A 2017-01-06 2018-01-04 Proceso para la preparación de compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidina-2,7-diona 3-sustituidos. MX384745B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017070437 2017-01-06
CN2017112149 2017-11-21
PCT/EP2018/050159 WO2018127525A1 (en) 2017-01-06 2018-01-04 PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED 5-AMINO-6H-THIAZOLO[4,5-d]PYRIMIDINE-2,7-DIONE COMPOUNDS

Publications (2)

Publication Number Publication Date
MX2019008116A MX2019008116A (es) 2019-09-04
MX384745B true MX384745B (es) 2025-03-14

Family

ID=60953862

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008116A MX384745B (es) 2017-01-06 2018-01-04 Proceso para la preparación de compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidina-2,7-diona 3-sustituidos.

Country Status (11)

Country Link
US (1) US11142534B2 (es)
EP (1) EP3568400B1 (es)
JP (2) JP7201598B2 (es)
KR (1) KR102602328B1 (es)
CN (1) CN110139868B (es)
AU (2) AU2018205994B2 (es)
CA (1) CA3048768A1 (es)
IL (1) IL267801B2 (es)
MX (1) MX384745B (es)
TW (1) TWI808068B (es)
WO (1) WO2018127525A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL307295A (en) * 2017-01-06 2023-11-01 Hoffmann La Roche Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[5,4-D]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran -2-yl]propyl]acetate
WO2018127525A1 (en) * 2017-01-06 2018-07-12 F. Hoffmann-La Roche Ag PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED 5-AMINO-6H-THIAZOLO[4,5-d]PYRIMIDINE-2,7-DIONE COMPOUNDS
US12012421B2 (en) 2017-07-07 2024-06-18 Hoffmann-La Roche Inc. Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
US12012420B2 (en) 2017-11-21 2024-06-18 Hoffmann-La Roche, Inc. Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
WO2025032082A1 (en) 2023-08-08 2025-02-13 F. Hoffmann-La Roche Ag Process for the preparation of 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476659A (en) 1982-11-09 1995-12-19 The Scripps Research Institute Cancerous B cell treatment using substituted nucleoside derivatives
US5166141A (en) 1983-11-01 1992-11-24 Scripps Clinic And Research Foundation Immunostimulating 7-deaza-7-oxa- and 7-deaza-7-oxo-analogs of 8-substituted-guanine-9-(1'-beta-D-aldoglycosidyl) derivatives and methods of treating test animals
US5041426A (en) 1987-12-21 1991-08-20 Brigham Young University Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides
FR2668153B1 (fr) * 1990-10-22 1995-03-31 Pasteur Merieux Serums Vacc Nouveaux composes ribonucleosides, leur procede de preparation et les medicaments les contenant.
AU727177B2 (en) 1996-10-16 2000-12-07 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof
EP1072607A3 (en) 1996-10-16 2001-09-12 ICN Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses therof
WO2005016235A2 (en) 2003-04-14 2005-02-24 The Regents Of The University Of California Combined use of impdh inhibitors with toll-like receptor agonists
EP1667694B1 (en) 2003-09-05 2010-04-28 Anadys Pharmaceuticals, Inc. Tlr7 ligands for the treatment of hepatitis c
ES2459368T3 (es) * 2004-12-17 2014-05-09 Anadys Pharmaceuticals, Inc. Compuestos de 3H-oxazolo y 3H-tiazolo[4,5-d]pirimidin-2-ona 3,5-disustituidos y 3,5,7-trisustituidos y profármacos de los mismos
CA2630463C (en) 2005-11-21 2015-01-06 Anadys Pharmaceuticals, Inc. Novel process for the preparation of 5-amino-3h-thiazolo[4,5-d]pyrimidin-2-one
CL2007001427A1 (es) 2006-05-22 2008-05-16 Novartis Ag Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
CA2655904C (en) 2006-06-22 2014-11-18 Anadys Pharmaceuticals, Inc. Prodrugs of 5-amino-3-(3'-deoxy-.beta.-d-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione
EP2040712B1 (en) 2006-07-18 2011-03-02 Anadys Pharmaceuticals, Inc. Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
BRPI0717741A2 (pt) * 2006-10-17 2014-04-08 Anadys Pharmaceuticals Inc Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença
WO2009026292A1 (en) 2007-08-20 2009-02-26 Anadys Pharmaceuticals, Inc. Dosing methods for treating disease
HUE053704T2 (hu) 2014-12-08 2021-07-28 Hoffmann La Roche 3-szubsztitutált 5-amino-6H-tiazolo[4,5-d]pirimidin-2,7-dion vegyületek vírusfertõzések kezelésére és megelõzésére
CN107427514B (zh) 2015-03-16 2021-07-13 豪夫迈·罗氏有限公司 使用tlr7激动剂和hbv衣壳装配抑制剂的组合治疗
CN107592864B (zh) 2015-05-12 2021-04-16 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的新的取代的氨基噻唑并嘧啶二酮
CN107820498B (zh) 2015-06-30 2020-06-19 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的取代的氨基噻唑并嘧啶二酮
WO2018127525A1 (en) * 2017-01-06 2018-07-12 F. Hoffmann-La Roche Ag PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED 5-AMINO-6H-THIAZOLO[4,5-d]PYRIMIDINE-2,7-DIONE COMPOUNDS

Also Published As

Publication number Publication date
US20200024287A1 (en) 2020-01-23
IL267801A (en) 2019-09-26
WO2018127525A1 (en) 2018-07-12
TWI808068B (zh) 2023-07-11
JP2023011699A (ja) 2023-01-24
AU2021258083A1 (en) 2021-11-25
MX2019008116A (es) 2019-09-04
TW201829419A (zh) 2018-08-16
JP7201598B2 (ja) 2023-01-10
KR102602328B1 (ko) 2023-11-16
CN110139868A (zh) 2019-08-16
US11142534B2 (en) 2021-10-12
EP3568400C0 (en) 2025-11-19
KR20190099492A (ko) 2019-08-27
EP3568400A1 (en) 2019-11-20
EP3568400B1 (en) 2025-11-19
AU2018205994A1 (en) 2019-06-13
CN110139868B (zh) 2021-07-09
IL267801B2 (en) 2023-07-01
JP2020504126A (ja) 2020-02-06
BR112019013884A2 (pt) 2020-03-03
IL267801B1 (en) 2023-03-01
CA3048768A1 (en) 2018-07-12
AU2018205994B2 (en) 2021-09-09

Similar Documents

Publication Publication Date Title
MX380516B (es) Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico
JOP20210001A1 (ar) مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2
GEAP202315746A (en) Protein tyrosine phosphatase inhibitors
MX2022015703A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf.
MX2010007375A (es) Nuevos derivados de lupano.
EA201992601A1 (ru) Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak
MX2020008816A (es) Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas.
MA41338A (fr) Composés de pyrazine pour le traitement de maladies infectieuses
PH12017501061A1 (en) 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
MX2010007374A (es) Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos.
MX2009008338A (es) Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio.
MX2021006902A (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica.
MY155255A (en) Spiro-oxindole compounds and their use as therapeutic agents
MX2009003874A (es) Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos.
WO2012018534A3 (en) Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
PH12015501560A1 (en) Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases
MX2020012827A (es) Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes.
MX2021012223A (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria.
PH12021552513A1 (en) Pyrrole compounds
NZ758449A (en) Heteroaromatic compounds useful in therapy
UY27577A1 (es) Inhibidores de la integrasa del vih
MX2019008116A (es) Proceso para la preparacion de compuestos de 5-amino-6h-tiazolo[4, 5-d]pirimidina-2,7-diona 3-sustituidos.
MX2025010256A (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
TW200716547A (en) Piperidin-4-yl-amide derivatives
PH12018502012A1 (en) Griseofulvin compound